The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2020

Filed:

Dec. 31, 2015
Applicant:

Genexine, Inc., Seongnam-si, Gyeonggi-do, KR;

Inventors:

Young Chul Sung, Seoul, KR;

Se Hwan Yang, Seoul, KR;

Mi Sun Byun, Bucheon-si, KR;

Sang In Yang, Daegu, KR;

Eun Ju Shin, Gyeonggi-do, KR;

Assignee:

GENEXINE, INC., Seongnam-si, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/605 (2006.01); A61K 38/26 (2006.01); C07K 16/00 (2006.01); C07K 19/00 (2006.01); A61P 1/00 (2006.01); A61P 1/12 (2006.01); A61P 3/08 (2006.01); A61P 3/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/605 (2013.01); A61K 38/26 (2013.01); A61P 1/00 (2018.01); A61P 1/12 (2018.01); A61P 3/08 (2018.01); A61P 3/10 (2018.01); C07K 16/00 (2013.01); C07K 19/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs. Accordingly, the fusion polypeptide of the present invention can be effectively applied to pharmaceutical drugs.


Find Patent Forward Citations

Loading…